Address: 1 Broadway, Cambridge, MA02142 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
Date: Saturday, June 3rd, 2023
Location: Boston Marriott Cambridge
Date: June 5-8, 2023
Location: Boston, MA
Booth: 2275-J
As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S. - West Coast)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D
Medicilon's drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. Among them, our chemistry team can carry out multi-dimensional business cooperation such as custom synthesis of compounds, compound library construction, SAR compound synthesis and screening, compound structure and bioactivity optimization, etc.
Medicilon's biology team offers a complete suite of biology services through protein expression, protein purification, protein crystallization analysis, and protein-compound co-crystallization, enzymology and cytological bioactivity screening, protein-protein and protein-small molecule affinity testing, virtual screening, and computer simulation-assisted drug design.
Medicilon's preclinical research services consist in three major parts: pharmacokinetics, disease transplantation models and drug safety evaluation. Our preclinical research services cover all of the aspects including design, in vivo studies, sample analysis, professional data analysis, IACUC review, and the preparation of application materials.
Medicilon has been actively developing new technologies platforms over the years, integrating emerging methods of green chemistry into its services, using currently popular photoredox chemistry, electrochemisty, catalyst screening, continuous reactions, etc., to provide our customers with high-quality economic solutions.
Cardiovascular and cerebrovascular diseases generally refer to ischemic or hemorrhagic diseases of the heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, and hypertension.Model evaluation is a critical step in testing results. Medicilon strictly follows the STAIR preclinical drug development strategy for stroke, and has rich experience in MCAO model establishment and a mature MCAO model system evaluation system.